Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients at least 18 years of age
Patients with a diagnosis of moderate to severe RA according to the revised (1987) ACR criteria
Patient in whom the treating physician has made the decision to commence RoActemra/Actemra treatment (in accordance with the local label). This can include patients who have received RoActemra/Actemra treatment within 8 weeks prior to the enrolment visit
Patient has given informed consent
You may not be if
Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment visit
Patients who have previously received RoActemra/Actemra in a clinical trial or for compassionate use
Patients who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra
Patients with a history of autoimmune disease or of any joint inflammatory disease other than RA
Clareo Health | Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)
